eloralintide vs cagrilintide Eli Lilly's Phase 2 Trial shows up to 20% Weight Loss with Promising Tolerability in Adults with Obesity Eloralintide, a selective amylin receptor
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet Eloralintide: What We Know About This New Weight Loss Drug in Testing Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace #Eloralintide vs #Cagrilintide Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept ScienceDirect Everyone and their mother is talking about eloralintide, the new amylin receptor agonist showing up to 20% body weight reduction in early trials. Gabriel Alizaidy, MD, MS
Pay in 4 interest-free payments of $6.29 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12



